Clinical Trials Logo

Clinical Trial Summary

Objectives: The overall objective is to evaluate the safety, efficacy and pharmacokinetics (PK) of rhASA treatment in patients with late infantile MLD. Methodology: This is a single center, open-label study of patients with late infantile MLD. Twelve patients will be enrolled in this study receiving a total of thirteen intravenous infusions of Metazym. One infusion will be given every other week for a period of half a year. After the half year the subjects will continue treatment every other week until safety data is available. Safety (AE/SAE) will be monitored at every visit during this period.


Clinical Trial Description

Test product, dose, mode of administration, batch No.: The lowest dose level will be evaluated as a single dose of 25 U/kg. The three upper dose levels will be evaluated as repeated doses. Patients in each cohort will receive one dose of enzyme every other week for a period of eight weeks, a total of five doses. Dosing will be performed as follows: Cohort 1: 25 U/kg as a single dose - hereafter 50 U/kg; Cohort 2: 100 U/kg; Cohort 3: 200 U/kg. Patients receiving the lowest dose as a single dose will receive the next dose level as a repeated dose. After twenty six weeks the subjects will continue treatment every other week until safety data is available. Safety (AE/SAE) will be monitored at every visit during this period. The dose will be adjusted monthly to account for changes in body weight. The infusion length will be dependent on the dose. Doses of 25 U/kg, 50 U/kg and 100 U/kg will be diluted in 50 ml isotonic sodium chloride and infused over 30 minutes. Infusion of 200 U/kg will be administered in the same manner except for an infusion time of 60 minutes. Duration of treatment: Half a year (26 weeks) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00418561
Study type Interventional
Source Takeda
Contact
Status Completed
Phase Phase 1
Start date January 22, 2007
Completion date March 27, 2008

See also
  Status Clinical Trial Phase
Recruiting NCT03725670 - Lentiviral Gene Therapy for MLD N/A
Withdrawn NCT05755568 - A Study to Learn About Metachromatic Leukodystrophy (MLD) in Children in Spain
Terminated NCT01963650 - Natural History Study of Children With Metachromatic Leukodystrophy
Active, not recruiting NCT01887938 - An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic Leukodystrophy Phase 1/Phase 2
Active, not recruiting NCT03771898 - A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy Phase 2
Completed NCT01510028 - Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD) Phase 1/Phase 2
Completed NCT01043640 - Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders Phase 2
Terminated NCT01372228 - Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders Phase 1/Phase 2